{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:40Z","timestamp":1781636080097,"version":"3.54.5"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review aims to synthesize recent evidence and accounts evaluating the utility of blue light cystoscopy (BLC) across the disease spectrum of bladder cancer, including its diagnostic, surveillance, and post-treatment uses, as well as its outpatient applications, economic impact, patient perspectives, and future directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>While initial studies on BLC suggested an advantage over traditional cystoscopy in terms of diagnostic power and recurrence rates for non-muscle invasive bladder cancer, recent studies are more equivocal on its benefits and suggest that the utilization of blue-light cystoscopy is more nuanced. Evidence is lacking on a clear superiority of blue light for all bladder cancer patients. Cost, logistics, and accuracy concerns indicate certain patients may benefit from this procedure more than others.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>BLC can be a valuable adjunct to white light cystoscopy in the management of bladder cancer. It provides high diagnostic sensitivity but there are questions surrounding its cost-effectiveness, positive predictive value, and its role in effective surveillance and reduction of tumor recurrence require further longitudinal and standardized investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11934-026-01322-7","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:27:38Z","timestamp":1771039658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-6115","authenticated-orcid":false,"given":"Ethan","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-3773","authenticated-orcid":false,"given":"Caroline","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-0510","authenticated-orcid":false,"given":"Aditya","family":"Sathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9073-9615","authenticated-orcid":false,"suffix":"3rd","given":"James E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8778-9759","authenticated-orcid":false,"given":"Charles C.","family":"Peyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"1","key":"1322_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00345-024-04949-8","volume":"42","author":"A Weber","year":"2024","unstructured":"Weber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P, et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024;42(1):237. https:\/\/doi.org\/10.1007\/s00345-024-04949-8.","journal-title":"World J Urol"},{"issue":"2","key":"1322_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","volume":"25","author":"B Al Hussein Al Awamlh","year":"2023","unstructured":"Al Hussein Al Awamlh B, Chang SS. Novel therapies for high-risk non-muscle invasive bladder cancer. Curr Oncol Rep. 2023;25(2):83\u201391. https:\/\/doi.org\/10.1007\/s11912-022-01350-9.","journal-title":"Curr Oncol Rep"},{"key":"1322_CR3","doi-asserted-by":"publisher","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466\u20135;\u00a0discussion 75\u2009\u2013\u20097.\u00a0https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031.","DOI":"10.1016\/j.eururo.2005.12.031"},{"issue":"5","key":"1322_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","volume":"19","author":"JY Teoh","year":"2022","unstructured":"Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol. 2022;19(5):280\u201394. https:\/\/doi.org\/10.1038\/s41585-022-00578-1.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1322_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5173\/ceju.2016.896","volume":"69","author":"SG Kata","year":"2016","unstructured":"Kata SG, Zreik A, Ahmad S, Chlosta P, Aboumarzouk O. Concurrent bladder cancer in patients undergoing photodynamic diagnostic ureterorenoscopy: how many lesions do we miss under white light cystoscopy? Cent Eur J Urol. 2016;69(4):334\u201340. https:\/\/doi.org\/10.5173\/ceju.2016.896.","journal-title":"Cent Eur J Urol"},{"key":"1322_CR6","doi-asserted-by":"publisher","first-page":"762027","DOI":"10.3389\/fsurg.2022.762027","volume":"9","author":"PM Mulawkar","year":"2022","unstructured":"Mulawkar PM, Sharma G, Tamhankar A, Shah U, Raheem R. Role of macroscopic image enhancement in diagnosis of Non-Muscle-Invasive bladder cancer: an analytical review. Front Surg. 2022;9:762027. https:\/\/doi.org\/10.3389\/fsurg.2022.762027.","journal-title":"Front Surg"},{"key":"1322_CR7","unstructured":"Leslie SW, Soon-Sutton TL, Aeddula NR. Bladder Cancer. StatPearls. Treasure Island (FL)2025."},{"issue":"1","key":"1322_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5489\/cuaj.777","volume":"4","author":"S Aldousari","year":"2010","unstructured":"Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56\u201364. https:\/\/doi.org\/10.5489\/cuaj.777.","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"1322_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","volume":"85","author":"T Strandgaard","year":"2024","unstructured":"Strandgaard T, Nordentoft I, Birkenkamp-Demtroder K, Salminen L, Prip F, Rasmussen J, et al. Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer. Eur Urol. 2024;85(1):82\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2023.07.014.","journal-title":"Eur Urol"},{"issue":"6","key":"1322_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s41669-024-00512-8","volume":"8","author":"O Clark","year":"2024","unstructured":"Clark O, Sarmento T, Eccleston A, Brinkmann J, Picoli R, Daliparthi V, et al. Economic impact of bladder cancer in the USA. Pharmacoeconomics- Open. 2024;8(6):837\u201345. https:\/\/doi.org\/10.1007\/s41669-024-00512-8.","journal-title":"Pharmacoeconomics- Open"},{"key":"1322_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/CEOR.S274951","volume":"12","author":"LJ Lee","year":"2020","unstructured":"Lee LJ, Kwon CS, Forsythe A, Mamolo CM, Masters ET, Jacobs IA. Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews. Clinicoecon Outcomes Res. 2020;12:693\u2013709. https:\/\/doi.org\/10.2147\/CEOR.S274951.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"1322_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/JOM.0000000000001242","volume":"60","author":"YL Jung","year":"2018","unstructured":"Jung YL, Tompa E, Longo C, Kalcevich C, Kim J, Song C, et al. The economic burden of bladder cancer due to occupational exposure. J Occup Environ Med. 2018;60(3):217\u201325. https:\/\/doi.org\/10.1097\/JOM.0000000000001242.","journal-title":"J Occup Environ Med"},{"issue":"7","key":"1322_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40273-023-01273-8","volume":"41","author":"DD Joyce","year":"2023","unstructured":"Joyce DD, Sharma V, Williams SB. Cost-effectiveness and economic impact of bladder cancer management: an updated review of the literature. Pharmacoeconomics. 2023;41(7):751\u201369. https:\/\/doi.org\/10.1007\/s40273-023-01273-8.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1322_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","volume":"32","author":"C Yeung","year":"2014","unstructured":"Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. 2014;32(11):1093\u2013104. https:\/\/doi.org\/10.1007\/s40273-014-0194-2.","journal-title":"Pharmacoeconomics"},{"key":"1322_CR15","unstructured":"New Drug Application for Cysview (hexaminolevulinate hydrochloride). [Internet]. Silver Spring (MD): Food and Drug Administration (US); [cited 2025 Nov 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022555Orig1s000MedR.pdf.: (2010). Accessed."},{"issue":"3","key":"1322_CR16","doi-asserted-by":"publisher","first-page":"e0122351","DOI":"10.1371\/journal.pone.0122351","volume":"10","author":"M Hayashi","year":"2015","unstructured":"Hayashi M, Fukuhara H, Inoue K, Shuin T, Hagiya Y, Nakajima M, et al. The effect of iron ion on the specificity of photodynamic therapy with 5-Aminolevulinic acid. PLoS ONE. 2015;10(3):e0122351. https:\/\/doi.org\/10.1371\/journal.pone.0122351.","journal-title":"PLoS ONE"},{"key":"1322_CR17","doi-asserted-by":"publisher","unstructured":"Nakai Y, Tatsumi Y, Hori S, Morizawa Y, Iida K, Onishi K, et al. 5\u2013Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating Heme synthesis. Oncol Rep. 2022;48(4). https:\/\/doi.org\/10.3892\/or.2022.8401.","DOI":"10.3892\/or.2022.8401"},{"key":"1322_CR18","doi-asserted-by":"publisher","unstructured":"Bazargani ST, Djaladat H, Schuckman AK, Hugen CM, Daneshmand S. Optimizing diagnosis of urothelial bladder cancer with blue light cystoscopy via recognition of False-Positive lesions. Videourology. 2018;32(2). https:\/\/doi.org\/10.1089\/vid.2017.0073.","DOI":"10.1089\/vid.2017.0073"},{"issue":"1","key":"1322_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/JU.0000000000004250","volume":"213","author":"A Ghoreifi","year":"2025","unstructured":"Ghoreifi A, Daneshmand S. Technical considerations to minimize false-positive findings in blue light cystoscopy for nonmuscle-invasive bladder cancer. J Urol. 2025;213(1):5\u20137. https:\/\/doi.org\/10.1097\/JU.0000000000004250.","journal-title":"J Urol"},{"issue":"4","key":"1322_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000003846.","journal-title":"J Urol"},{"issue":"4","key":"1322_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016;196(4):1021\u20139. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049.","journal-title":"J Urol"},{"issue":"6","key":"1322_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F, et al. European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u2014a summary of the 2024 Guidelines Update. Eur Urol. 2024;86(6):531\u201349. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027.","journal-title":"Eur Urol"},{"key":"1322_CR23","unstructured":"Guidelines NCCN. Version 1.2025 bladder cancer. National Comprehensive Cancer Network."},{"issue":"5","key":"1322_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/iju.14210","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, et al. Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: revision working position paper. Int J Urol. 2020;27(5):362\u20138. https:\/\/doi.org\/10.1111\/iju.14210.","journal-title":"Int J Urol"},{"issue":"8","key":"1322_CR25","doi-asserted-by":"publisher","first-page":"E424","DOI":"10.5489\/cuaj.7367","volume":"15","author":"B Bhindi","year":"2021","unstructured":"Bhindi B, Kool R, Kulkarni GS, Siemens DR, Aprikian AG, Breau RH, et al. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - full-text. Can Urol Assoc J. 2021;15(8):E424\u201360. https:\/\/doi.org\/10.5489\/cuaj.7367.","journal-title":"Can Urol Assoc J"},{"key":"1322_CR26","doi-asserted-by":"publisher","unstructured":"Jin Y-H, Zeng X-T, Liu T-Z, Bai Z-M, Dou Z-L, Ding D-G, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Military Med Res. 2022;9(1). https:\/\/doi.org\/10.1186\/s40779-022-00406-y.","DOI":"10.1186\/s40779-022-00406-y"},{"key":"1322_CR27","doi-asserted-by":"publisher","first-page":"104554","DOI":"10.1016\/j.pdpdt.2025.104554","volume":"53","author":"R Taoka","year":"2025","unstructured":"Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, et al. Efficacy of photodynamic diagnosis for non-muscle invasive bladder cancer: exploratory subject-based analysis in a prospective, single-arm, multicenter phase III trial. Photodiagnosis Photodyn Ther. 2025;53:104554. https:\/\/doi.org\/10.1016\/j.pdpdt.2025.104554.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"7","key":"1322_CR28","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/cancers16071268","volume":"16","author":"S-S Ladi-Seyedian","year":"2024","unstructured":"Ladi-Seyedian S-S, Ghoreifi A, Konety B, Pohar K, Holzbeierlein JM, Taylor J, et al. Racial differences in the detection rate of bladder cancer using blue light cystoscopy: insights from a multicenter registry. Cancers. 2024;16(7):1268. https:\/\/doi.org\/10.3390\/cancers16071268.","journal-title":"Cancers"},{"issue":"3","key":"1322_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.21873\/cdp.10027","volume":"1","author":"K Watanabe","year":"2021","unstructured":"Watanabe K, Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, et al. Significance of 5-aminolevulinic acid-mediated photodynamic diagnosis following standard transurethral resection in non-muscle invasive bladder cancer. Cancer Diagn Progn. 2021;1(3):201\u20135. https:\/\/doi.org\/10.21873\/cdp.10027.","journal-title":"Cancer Diagn Progn"},{"issue":"4","key":"1322_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/21681805.2021.1928746","volume":"55","author":"M Andersson","year":"2021","unstructured":"Andersson M, Berger M, Zieger K, Malmstrom PU, Blackberg M. The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem. Scand J Urol. 2021;55(4):263\u20137. https:\/\/doi.org\/10.1080\/21681805.2021.1928746.","journal-title":"Scand J Urol"},{"issue":"1","key":"1322_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4081\/aiua.2017.1.39","volume":"89","author":"V Lacetera","year":"2017","unstructured":"Lacetera V, Cantoro U, Montesi L, Cantoro D, Cervelli B, Cicetti A, et al. Blue light cystoscopy with hexylaminolevulinate: our 7 years experience. Arch Ital Urol Androl. 2017;89(1):39\u201341. https:\/\/doi.org\/10.4081\/aiua.2017.1.39.","journal-title":"Arch Ital Urol Androl"},{"key":"1322_CR32","doi-asserted-by":"publisher","unstructured":"Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM et al. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. Urol Oncol. 2018;36(8):361 e1- e6. https:\/\/doi.org\/10.1016\/j.urolonc.2018.04.013","DOI":"10.1016\/j.urolonc.2018.04.013"},{"issue":"12","key":"1322_CR33","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1089\/end.2021.0313","volume":"35","author":"M Morelli","year":"2021","unstructured":"Morelli M, Baboudjian M, Vanacore D, Gondran-Tellier B, McManus R, Karsenty G, et al. Early photodynamic diagnosis cystoscopy after Bacillus Calmette-Guerin (BCG) induction for high-risk nonmuscle invasive bladder cancer significantly increased the detection of BCG refractory tumors. J Endourol. 2021;35(12):1824\u20138. https:\/\/doi.org\/10.1089\/end.2021.0313.","journal-title":"J Endourol"},{"issue":"4","key":"1322_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1464-410x.2011.10374.x","volume":"109","author":"B Geavlete","year":"2012","unstructured":"Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non\u2010muscle\u2010invasive bladder cancer (NMIBC)? BJU Int. 2012;109(4):549\u201356. https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10374.x.","journal-title":"BJU Int"},{"issue":"2","key":"1322_CR35","doi-asserted-by":"publisher","first-page":"235237352513243","DOI":"10.1177\/23523735251324318","volume":"11","author":"IM McElree","year":"2025","unstructured":"McElree IM, Steinberg RL, Mott SL, Hougen HY, O\u2019Donnell MA, Packiam VT. The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC. Bladder Cancer. 2025;11(2):23523735251324318. https:\/\/doi.org\/10.1177\/23523735251324318.","journal-title":"Bladder Cancer"},{"issue":"5","key":"1322_CR36","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/bco2.250","volume":"4","author":"K Chan","year":"2023","unstructured":"Chan K, Hampson A, Hayes J, Rabinowitz J, Vasdev N. Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: histopathological characteristics and recurrence rates in a single UK centre study. BJUI Compass. 2023;4(5):568\u201374. https:\/\/doi.org\/10.1002\/bco2.250.","journal-title":"BJUI Compass"},{"issue":"2","key":"1322_CR37","doi-asserted-by":"publisher","first-page":"e1099","DOI":"10.1016\/j.urolonc.2022.10.026","volume":"41","author":"M Alsyouf","year":"2023","unstructured":"Alsyouf M, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, et al. Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light? Urol Oncol. 2023;41(2):e1099\u201314. https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.026.","journal-title":"Urol Oncol"},{"issue":"4","key":"1322_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4081\/aiua.2022.4.424","volume":"94","author":"V Lorusso","year":"2022","unstructured":"Lorusso V, Doisy L, Granata AM, Gregori A, Manfredi C, Spirito L, et al. Could we safely omit a repeat transurethral resection of the bladder (re-TURB) after Hexaminolevulinate photodynamic diagnostics (PDD)-TURB? Arch Ital Urol Androl. 2022;94(4):424\u20137. https:\/\/doi.org\/10.4081\/aiua.2022.4.424.","journal-title":"Arch Ital Urol Androl"},{"issue":"3","key":"1322_CR39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/JU.0000000000002308","volume":"207","author":"MR Chappidi","year":"2022","unstructured":"Chappidi MR, Yang H, Meng MV, Bivalacqua TJ, Daneshmand S, Holzbeierlein JM, et al. Utility of blue light cystoscopy for post-bacillus Calmette-Guerin bladder cancer recurrence detection: implications for clinical trial recruitment and study comparisons. J Urol. 2022;207(3):534\u201340. https:\/\/doi.org\/10.1097\/JU.0000000000002308.","journal-title":"J Urol"},{"issue":"1","key":"1322_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bju.15166","volume":"127","author":"Y Lotan","year":"2021","unstructured":"Lotan Y, Chaplin I, Ahmadi H, Meng X, Roberts S, Ladi-Seyedian S, et al. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. BJU Int. 2021;127(1):108\u201313. https:\/\/doi.org\/10.1111\/bju.15166.","journal-title":"BJU Int"},{"issue":"5","key":"1322_CR41","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","volume":"199","author":"S Daneshmand","year":"2018","unstructured":"Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, et al. Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study. J Urol. 2018;199(5):1158\u201365. https:\/\/doi.org\/10.1016\/j.juro.2017.11.096.","journal-title":"J Urol"},{"issue":"6","key":"1322_CR42","first-page":"1003","volume":"3","author":"R Colombo","year":"2007","unstructured":"Colombo R, Naspro R, Bellinzoni P, Fabbri F, Guazzoni G, Scattoni V, et al. Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Ther Clin Risk Manag. 2007;3(6):1003\u20137.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"1322_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.eururo.2004.10.025","volume":"47","author":"W Loidl","year":"2005","unstructured":"Loidl W, Schmidbauer J, Susani M, Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol. 2005;47(3):323\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2004.10.025.","journal-title":"Eur Urol"},{"issue":"2","key":"1322_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jnci.2016.03.002","volume":"28","author":"K Sfetsas","year":"2016","unstructured":"Sfetsas K, Mitropoulos D. Reducing understaging of bladder cancer with the aid of photodynamic cystoscopy. J Egypt Natl Canc Inst. 2016;28(2):89\u201394. https:\/\/doi.org\/10.1016\/j.jnci.2016.03.002.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"1","key":"1322_CR45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.juro.2007.03.028","volume":"178","author":"Y Fradet","year":"2007","unstructured":"Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178(1):68\u201373. https:\/\/doi.org\/10.1016\/j.juro.2007.03.028.","journal-title":"J Urol"},{"issue":"10","key":"1322_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrurol.2014.245","volume":"11","author":"S Daneshmand","year":"2014","unstructured":"Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11(10):589\u201396. https:\/\/doi.org\/10.1038\/nrurol.2014.245.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1322_CR47","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/bju.16364","volume":"134","author":"R Sari Motlagh","year":"2024","unstructured":"Sari Motlagh R, Ghoreifi A, Yanagisawa T, Kawada T, Ahyai S, Merseburger AS, et al. Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis. BJU Int. 2024;134(4):526\u201333. https:\/\/doi.org\/10.1111\/bju.16364.","journal-title":"BJU Int"},{"issue":"6","key":"1322_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.clgc.2023.04.011","volume":"21","author":"S Das","year":"2023","unstructured":"Das S, Gu L, Eve CT, Parrish J, De Hoedt AM, McKee C, et al. The impact of blue light cystoscopy use among nonmuscle invasive bladder cancer patients in an equal access setting: implications on recurrence and time to recurrence. Clin Genitourin Cancer. 2023;21(6):711. https:\/\/doi.org\/10.1016\/j.clgc.2023.04.011.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"1322_CR49","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/bco2.215","volume":"4","author":"M Miyake","year":"2023","unstructured":"Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, et al. Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: a comparative study from experienced institutes. BJUI Compass. 2023;4(3):305\u201313. https:\/\/doi.org\/10.1002\/bco2.215.","journal-title":"BJUI Compass"},{"key":"1322_CR50","doi-asserted-by":"publisher","first-page":"103574","DOI":"10.1016\/j.pdpdt.2023.103574","volume":"42","author":"R Nakagawa","year":"2023","unstructured":"Nakagawa R, Nohara T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, et al. Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival. Photodiagnosis Photodyn Ther. 2023;42:103574. https:\/\/doi.org\/10.1016\/j.pdpdt.2023.103574.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"10","key":"1322_CR51","doi-asserted-by":"publisher","first-page":"EVIDoa2200092","DOI":"10.1056\/EVIDoa2200092","volume":"1","author":"R Heer","year":"2022","unstructured":"Heer R, Lewis R, Vadiveloo T, Yu G, Mariappan P, Cresswell J, et al. A randomized trial of photodynamic surgery in Non-Muscle-Invasive bladder cancer. NEJM Evid. 2022;1(10):EVIDoa2200092. https:\/\/doi.org\/10.1056\/EVIDoa2200092.","journal-title":"NEJM Evid"},{"issue":"10","key":"1322_CR52","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1007\/s00345-021-03719-0","volume":"39","author":"M Gierth","year":"2021","unstructured":"Gierth M, Breyer J, Zeman F, Fritsche HM, Cordes J, Karl A, et al. The HELENA study: Hexvix((R))-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study. World J Urol. 2021;39(10):3799\u2013805. https:\/\/doi.org\/10.1007\/s00345-021-03719-0.","journal-title":"World J Urol"},{"key":"1322_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.urology.2019.12.002","volume":"137","author":"D Drejer","year":"2020","unstructured":"Drejer D, Moltke AL, Nielsen AM, Lam GW, Jensen JB. DaBlaCa-11: photodynamic diagnosis in flexible cystoscopy-a randomized study with focus on recurrence. Urology. 2020;137:91\u20136. https:\/\/doi.org\/10.1016\/j.urology.2019.12.002.","journal-title":"Urology"},{"issue":"6","key":"1322_CR54","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bju.15723","volume":"130","author":"P Maisch","year":"2022","unstructured":"Maisch P, Koziarz A, Vajgrt J, Narayan V, Kim MH, Dahm P. Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane review. BJU Int. 2022;130(6):730\u201340. https:\/\/doi.org\/10.1111\/bju.15723.","journal-title":"BJU Int"},{"key":"1322_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euros.2021.06.011","volume":"31","author":"R Veeratterapillay","year":"2021","unstructured":"Veeratterapillay R, Gravestock P, Nambiar A, Gupta A, Aboumarzouk O, Rai B, et al. Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer. Eur Urol Open Sci. 2021;31:17\u201327. https:\/\/doi.org\/10.1016\/j.euros.2021.06.011.","journal-title":"Eur Urol Open Sci"},{"key":"1322_CR56","doi-asserted-by":"publisher","first-page":"103220","DOI":"10.1016\/j.pdpdt.2022.103220","volume":"41","author":"H Zhao","year":"2023","unstructured":"Zhao H, Peng P, Luo Z, Liu H, Sun J, Wang X, et al. Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials. Photodiagnosis Photodyn Ther. 2023;41:103220. https:\/\/doi.org\/10.1016\/j.pdpdt.2022.103220.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1322_CR57","doi-asserted-by":"publisher","DOI":"10.1089\/vid.2017.0073","author":"ST Bazargani","year":"2018","unstructured":"Bazargani ST, Djaladat H, Schuckman AK, Hugen CM, Daneshmand S. Optimizing diagnosis of urothelial bladder cancer with blue light cystoscopy via recognition of false-positive lesions. Videourology (New Rochelle). 2018. https:\/\/doi.org\/10.1089\/vid.2017.0073.","journal-title":"Videourology (New Rochelle)"},{"issue":"5S","key":"1322_CR58","doi-asserted-by":"publisher","first-page":"e1168","DOI":"10.1097\/01.JU.0001009548.76580.ba.18","volume":"211","author":"H Li","year":"2024","unstructured":"Li H, Hu H, Huang J, Ma L, Zhang S, Guo J, et al. MP71-18 Blue light cystoscopy versus white light cystoscopy for the detection of bladder cancer using modern hd 4k equipment: an analysis of pivotal trial and real-world data in China. J Urol. 2024;211(5S):e1168. https:\/\/doi.org\/10.1097\/01.JU.0001009548.76580.ba.18.","journal-title":"J Urol"},{"issue":"5","key":"1322_CR59","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.eururo.2014.06.037","volume":"66","author":"JA Witjes","year":"2014","unstructured":"Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol. 2014;66(5):863\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2014.06.037.","journal-title":"Eur Urol"},{"issue":"Supplement 4","key":"1322_CR60","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1097\/ju.0000000000000857.06","volume":"203","author":"S Regmi","year":"2020","unstructured":"Regmi S, Kalapara A, Alford A, Daneshmand S, Porten S, Pohar K, et al. MP24-06\u2003GENDER BASED VARIATIONS IN THE DETECTION OF BLADDER CANCER WITH BLUE LIGHT CYSTOSCOPY: INSIGHTS FROM A MULTICENTER REGISTRY. J Urol. 2020;203(Supplement 4):e349. https:\/\/doi.org\/10.1097\/ju.0000000000000857.06.","journal-title":"J Urol"},{"key":"1322_CR61","unstructured":"Bono MJ, Leslie SW. Uncomplicated Urinary Tract Infections. StatPearls. Treasure Island (FL)2025."},{"issue":"4","key":"1322_CR62","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.urology.2009.04.095","volume":"74","author":"RO Draga","year":"2009","unstructured":"Draga RO, Grimbergen MC, Kok ET, Jonges TN, Bosch JL. Predictors of false positives in 5-aminolevulinic acid-induced photodynamic diagnosis of bladder carcinoma: identification of patient groups that may benefit most from highly specific optical diagnostics. Urology. 2009;74(4):851\u20136. https:\/\/doi.org\/10.1016\/j.urology.2009.04.095.","journal-title":"Urology"},{"issue":"4","key":"1322_CR63","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.eururo.2009.09.037","volume":"57","author":"RO Draga","year":"2010","unstructured":"Draga RO, Grimbergen MC, Kok ET, Jonges TN, van Swol CF, Bosch JL. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy. Eur Urol. 2010;57(4):655\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2009.09.037.","journal-title":"Eur Urol"},{"issue":"6","key":"1322_CR64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/iju.70045","volume":"32","author":"T Sano","year":"2025","unstructured":"Sano T, Ohe C, Nakamoto T, Yoshida T, Taniguchi H, Yanishi M, et al. Pathological analysis of false-positive samples in photodynamic diagnosis of bladder cancer according to a history of intravesical Bacillus Calmette\u2010Gu\u00e9rin therapy. Int J Urol. 2025;32(6):729\u201336. https:\/\/doi.org\/10.1111\/iju.70045.","journal-title":"Int J Urol"},{"issue":"3","key":"1322_CR65","first-page":"6269","volume":"19","author":"S Gravas","year":"2012","unstructured":"Gravas S, Efstathiou K, Zachos I, Melekos MD, Tzortzis V. Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride? Can J Urol. 2012;19(3):6269\u201373.","journal-title":"Can J Urol"},{"issue":"1","key":"1322_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2024","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024). J Urol. 2024;212(1):3\u201310. https:\/\/doi.org\/10.1097\/JU.0000000000003981.","journal-title":"J Urol"},{"issue":"3","key":"1322_CR67","doi-asserted-by":"publisher","first-page":"123","DOI":"10.14740\/wjon1210","volume":"10","author":"A Cassell","year":"2019","unstructured":"Cassell A, Yunusa B, Jalloh M, Mbodji MM, Diallo A, Ndoye M, et al. Non-Muscle invasive bladder cancer: a review of the current trend in Africa. World J Oncol. 2019;10(3):123\u201331. https:\/\/doi.org\/10.14740\/wjon1210.","journal-title":"World J Oncol"},{"issue":"1","key":"1322_CR68","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s13193-016-0586-1","volume":"8","author":"SR Krishna","year":"2017","unstructured":"Krishna SR, Konety BR. Current concepts in the management of muscle invasive bladder cancer. Indian J Surg Oncol. 2017;8(1):74\u201381. https:\/\/doi.org\/10.1007\/s13193-016-0586-1.","journal-title":"Indian J Surg Oncol"},{"issue":"1","key":"1322_CR69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bju.15614","volume":"130","author":"H Ahmadi","year":"2022","unstructured":"Ahmadi H, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, et al. Role of blue\u2010light cystoscopy in detecting invasive bladder tumours: data from a multi\u2010institutional registry. BJU Int. 2022;130(1):62\u20137. https:\/\/doi.org\/10.1111\/bju.15614.","journal-title":"BJU Int"},{"issue":"2","key":"1322_CR70","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1590\/S1677-5538.IBJU.2020.99.01","volume":"46","author":"J Hamad","year":"2020","unstructured":"Hamad J, McCloskey H, Milowsky MI, Royce T, Smith A. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Int Braz J Urol. 2020;46(2):169\u201384. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2020.99.01.","journal-title":"Int Braz J Urol"},{"issue":"2","key":"1322_CR71","first-page":"6682","volume":"20","author":"SS Garfield","year":"2013","unstructured":"Garfield SS, Gavaghan MB, Armstrong SO, Jones JS. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: united States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol. 2013;20(2):6682\u20139.","journal-title":"Can J Urol"},{"issue":"1","key":"1322_CR72","doi-asserted-by":"publisher","first-page":"10.e7","DOI":"10.1016\/j.urolonc.2021.05.023","volume":"40","author":"SB Williams","year":"2022","unstructured":"Williams SB, Gavaghan MB, Fernandez A, Daneshmand S, Kamat AM. Macro and microeconomics of blue light cystoscopy with CYSVIEW\u00ae in non-muscle invasive bladder cancer. Urol Oncol. 2022;40(1):10.e7-.e2. https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.023.","journal-title":"Urol Oncol"},{"issue":"4","key":"1322_CR73","doi-asserted-by":"publisher","first-page":"207.e9","DOI":"10.1016\/j.urolonc.2022.11.014","volume":"41","author":"ND Shore","year":"2023","unstructured":"Shore ND, Gavaghan MB. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity? Urol Oncol. 2023;41(4):207.e9-.e16. https:\/\/doi.org\/10.1016\/j.urolonc.2022.11.014.","journal-title":"Urol Oncol"},{"issue":"12","key":"1322_CR74","first-page":"1","volume":"21","author":"H Ontario","year":"2021","unstructured":"Ontario H. Enhanced visualization methods for first transurethral resection of bladder tumour in suspected non-muscle-invasive bladder cancer: a health technology assessment. Ont Health Technol Assess Ser. 2021;21(12):1\u2013123.","journal-title":"Ont Health Technol Assess Ser"},{"issue":"6","key":"1322_CR75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5489\/cuaj.4568","volume":"11","author":"Z Klaassen","year":"2017","unstructured":"Klaassen Z, Li K, Kassouf W, Black PC, Dragomir A, Kulkarni GS. Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. Can Urol Assoc J. 2017;11(6):173\u201381. https:\/\/doi.org\/10.5489\/cuaj.4568.","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"1322_CR76","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1080\/13696998.2023.2267929","volume":"26","author":"J Belsey","year":"2023","unstructured":"Belsey J. A cost-consequences and budget impact analysis of blue light-guided cystoscopy with hexvix in patients diagnosed with non-muscle-invasive bladder cancer in France. J Med Econ. 2023;26(1):1398\u2013406. https:\/\/doi.org\/10.1080\/13696998.2023.2267929.","journal-title":"J Med Econ"},{"issue":"8","key":"1322_CR77","first-page":"474","volume":"6","author":"K Stav","year":"2004","unstructured":"Stav K, Leibovici D, Goren E, Livshitz A, Siegel YI, Lindner A, et al. Adverse effects of cystoscopy and its impact on patients\u2019 quality of life and sexual performance. Isr Med Assoc J. 2004;6(8):474\u20138.","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"1322_CR78","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2017.58.1.48","volume":"58","author":"NF Casteleijn","year":"2017","unstructured":"Casteleijn NF, Vriesema JL, Stomps SP, Van Balen OLWB, Cornel EB. The effect of office based flexible and rigid cystoscopy on pain experience in female patients. Investigative and Clinical Urology. 2017;58(1):48. https:\/\/doi.org\/10.4111\/icu.2017.58.1.48.","journal-title":"Investigative and Clinical Urology"},{"issue":"4","key":"1322_CR79","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1046\/j.1464-4096.2001.01899.x","volume":"89","author":"DM Burke","year":"2002","unstructured":"Burke DM, Shackley DC, O\u2019Reilly PH. <article-title update=\"added\">The community\u2010based morbidity of flexible cystoscopy. BJU Int. 2002;89(4):347\u20139. https:\/\/doi.org\/10.1046\/j.1464-4096.2001.01899.x.","journal-title":"BJU Int"},{"issue":"1","key":"1322_CR80","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.urology.2014.03.006","volume":"84","author":"JA Witjes","year":"2014","unstructured":"Witjes JA, Gomella LG, Stenzl A, Chang SS, Zaak D, Grossman HB. Safety of hexaminolevulinate for blue light cystoscopy in bladder Cancer. A combined analysis of the trials used for registration and postmarketing data. Urology. 2014;84(1):122\u20136. https:\/\/doi.org\/10.1016\/j.urology.2014.03.006.","journal-title":"Urology"},{"issue":"9","key":"1322_CR81","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1399-6576.2006.01110.x","volume":"50","author":"L Colapaoli","year":"2006","unstructured":"Colapaoli L, Thorsen J, Nopp A, Guttormsen AB. A case of anaphylactic shock possibly caused by intravesical hexvix. Acta Anaesthesiol Scand. 2006;50(9):1165\u20137. https:\/\/doi.org\/10.1111\/j.1399-6576.2006.01110.x.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"8","key":"1322_CR82","doi-asserted-by":"publisher","first-page":"e3821","DOI":"10.1016\/j.urolonc.2022.04.012","volume":"40","author":"KS Pohar","year":"2022","unstructured":"Pohar KS, Patel S, Lotan Y, Trabulsi E, Woods M, Downs T, et al. Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: results from a phase III, comparative, multi-center study. Urol Oncol. 2022;40(8):e3821\u20136. https:\/\/doi.org\/10.1016\/j.urolonc.2022.04.012.","journal-title":"Urol Oncol"},{"issue":"1","key":"1322_CR83","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/bju.14481","volume":"123","author":"AB Smith","year":"2019","unstructured":"Smith AB, Daneshmand S, Patel S, Pohar K, Trabulsi E, Woods M, et al. Patient\u2010reported outcomes of blue\u2010light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU Int. 2019;123(1):35\u201341. https:\/\/doi.org\/10.1111\/bju.14481.","journal-title":"BJU Int"},{"issue":"S6","key":"1322_CR84","doi-asserted-by":"publisher","first-page":"S727","DOI":"10.21037\/tau.2018.09.10","volume":"7","author":"N Almassi","year":"2018","unstructured":"Almassi N, Pietzak E. The patient\u2019s perspective on blue light flexible cystoscopy: insight from a prospective clinical study. Transl Androl Urol. 2018;7(S6):S727-8. https:\/\/doi.org\/10.21037\/tau.2018.09.10.","journal-title":"Transl Androl Urol"},{"issue":"7","key":"1322_CR85","doi-asserted-by":"publisher","first-page":"e33117","DOI":"10.1016\/j.urolonc.2015.04.002","volume":"33","author":"MA Feuerstein","year":"2015","unstructured":"Feuerstein MA, Jacobs M, Piciocchi A, Bochner B, Pusic A, Fayers P, et al. Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. Urologic Oncology: Seminars Original Investigations. 2015;33(7):e33117\u201323. https:\/\/doi.org\/10.1016\/j.urolonc.2015.04.002.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"1322_CR86","unstructured":"Lyman MB, Plappert A, Charles T. M. End of life product notice. Karl Storz; 2025."},{"key":"1322_CR87","doi-asserted-by":"publisher","unstructured":"Arnold Zieger KE, Young-Halvorsen K, Malmstr\u00f6m P-U, MP08-15 The role of flexible blue light cystoscopy in surveillance of non-muscle invasive bladder cancer. results from a nordic registry. J Urol. 2023;209(Supplement 4). https:\/\/doi.org\/10.1097\/ju.0000000000003223.15.","DOI":"10.1097\/ju.0000000000003223.15"},{"issue":"1","key":"1322_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/03915603241282407","volume":"92","author":"V Bhatt","year":"2025","unstructured":"Bhatt V, Malshy K, Homer A, Golijanin B, Golijanin D. Investigating the association between blue light cystoscopy utilization and social determinants of health. Urologia. 2025;92(1):44\u201350. https:\/\/doi.org\/10.1177\/03915603241282407.","journal-title":"Urologia"},{"issue":"1","key":"1322_CR89","doi-asserted-by":"publisher","first-page":"21484","DOI":"10.1038\/s41598-023-48882-z","volume":"13","author":"S Chang","year":"2023","unstructured":"Chang S, Bermoy ME, Chang SS, Scarpato KR, Luckenbaugh AN, Kolouri S, et al. Enhancing the image quality of blue light cystoscopy through green-hue correction and fogginess removal. Sci Rep. 2023;13(1):21484. https:\/\/doi.org\/10.1038\/s41598-023-48882-z.","journal-title":"Sci Rep"},{"issue":"1","key":"1322_CR90","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s43856-024-00705-6","volume":"4","author":"S Chang","year":"2024","unstructured":"Chang S, Wintergerst GA, Carlson C, Yin H, Scarpato KR, Luckenbaugh AN, et al. Low-cost and label-free blue light cystoscopy through digital staining of white light cystoscopy videos. Commun Med (Lond). 2024;4(1):269. https:\/\/doi.org\/10.1038\/s43856-024-00705-6.","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"1322_CR91","doi-asserted-by":"publisher","first-page":"11629","DOI":"10.1038\/s41598-021-91081-x","volume":"11","author":"N Ali","year":"2021","unstructured":"Ali N, Bolenz C, Todenhofer T, Stenzel A, Deetmar P, Kriegmair M, et al. Deep learning-based classification of blue light cystoscopy imaging during transurethral resection of bladder tumors. Sci Rep. 2021;11(1):11629. https:\/\/doi.org\/10.1038\/s41598-021-91081-x.","journal-title":"Sci Rep"},{"key":"1322_CR92","unstructured":"The Impact of PDD During TURB for NMIBC (TUR_BLUE). [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 5]. Identifier NCT06548438. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06548438."},{"key":"1322_CR93","unstructured":"Blue Light Cystoscopy With Cysview\u00ae Registry (BLCCR). [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 5]. Identifier NCT02660645. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02660645."},{"key":"1322_CR94","unstructured":"Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 5]. Identifier NCT06525571. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06525571."},{"key":"1322_CR95","unstructured":"Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 5]. Identifier NCT06948552. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06948552."},{"key":"1322_CR96","unstructured":"Vesical Imaging-Reporting and Data System (VI-RADS). Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) (CUT-less) [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 5]. Identifier NCT05962541. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05962541."},{"key":"1322_CR97","doi-asserted-by":"publisher","first-page":"101617","DOI":"10.1016\/j.pdpdt.2019.101617","volume":"29","author":"H Fukuhara","year":"2020","unstructured":"Fukuhara H, Kurabayashi A, Furihata M, Setuda S, Takahashi K, Murakami K, et al. 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence ureterorenoscopy for urinary upper tract urothelial carcinoma. Photodiagnosis Photodyn Ther. 2020;29:101617. https:\/\/doi.org\/10.1016\/j.pdpdt.2019.101617.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1322_CR98","doi-asserted-by":"publisher","first-page":"102841","DOI":"10.1016\/j.eucr.2024.102841","volume":"56","author":"C Klose","year":"2024","unstructured":"Klose C, Gibbs EM, Waddell B, Baird B, Lyon T, Pak R. Intravesical hexyl-aminolevulinate used to detect upper tract carcinoma in situ during surveillance ureteroscopy: A case report and review. Urol Case Rep. 2024;56:102841. https:\/\/doi.org\/10.1016\/j.eucr.2024.102841.","journal-title":"Urol Case Rep"},{"issue":"1","key":"1322_CR99","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1089\/cren.2016.0031","volume":"2","author":"A Shukla","year":"2016","unstructured":"Shukla A, Wingate JT, Baker KC, Brand TC. Hexaminolevulinate blue-light cystoscopy in a patient with metastatic melanoma of the bladder. J Endourol Case Rep. 2016;2(1):68\u201370. https:\/\/doi.org\/10.1089\/cren.2016.0031.","journal-title":"J Endourol Case Rep"},{"issue":"4","key":"1322_CR100","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.euf.2021.09.025","volume":"8","author":"P Lewicki","year":"2022","unstructured":"Lewicki P, Arenas-Gallo C, Qiu Y, Venkat S, Basourakos SP, Scherr D, et al. Underutilization of blue light cystoscopy for bladder cancer in the united States. Eur Urol Focus. 2022;8(4):968\u201371. https:\/\/doi.org\/10.1016\/j.euf.2021.09.025.","journal-title":"Eur Urol Focus"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-026-01322-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:14:55Z","timestamp":1781633695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-026-01322-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1007\/s11934-026-01322-7","relation":{},"ISSN":["1534-6285"],"issn-type":[{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors. All images included are fully deidentified clinical examples used for illustrative purposes only.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}